Biotts

Biotts is a private, pre-revenue biotech firm developing a proprietary polymer-based platform for transdermal drug delivery. The company aims to overcome the limitations of traditional oral and injectable routes by creating patches and topical formulations that can deliver a wider range of molecules, including those with larger molecular weights. While specific pipeline details are not publicly disclosed, its technology holds potential across multiple therapeutic areas requiring sustained or controlled drug release. The company's success will hinge on validating its platform with lead candidates, securing strategic partnerships, and navigating the complex regulatory pathway for novel drug delivery systems.

Proprietary polymer-based systems designed to enhance transdermal delivery of drugs, potentially enabling the delivery of larger or less permeable molecules through the skin.

The transdermal delivery space is competitive, featuring large established players (e.g., LTS Lohmann, Viatris) and numerous startups exploring diverse technologies like microneedles, sonophoresis, and chemical enhancers. Biotts competes by specializing in polymer-based systems, aiming to differentiate on the breadth of molecules deliverable and formulation versatility.